Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

Table 1

Demographic and clinical characteristics of the premature infants who received intravitreal bevacizumab as primary therapy for ROP.

Eyes (patients)	74 (37)
Male/female	17/20
Unique/multiple pregnancy	29/8
Mean gestational age (wk)	28.89
Mean birth weight (g)	1218.35
Mean injection time (postmenstrual age/postnatal age, wk)	35.11/6.22
Number of eyes (%) with regression after bevacizumab injection alone	63 (85.13)